打响血液肿瘤升维战,阿斯利康的另一面

氨基观察
26 Jun

血液肿瘤的治疗,需要更多突破。亚型众多、创新疗法不够、耐药问题需要解决、创新疗法的可及性需要进一步提升…….一系列因素都导致了血液肿瘤的治疗需求远未被满足。中国更是如此。如下图所示,我国血液肿瘤患者5年生存率,相较于美国等发达国家和地区而言,仍有较大差距[1]。图片来源:开源证券研究报告《血液肿瘤创新技术层出,各亚型均有孵化“重磅炸弹”药物潜力》患者的需求,自然是药企攻坚的方向。国内方面,包括...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10